[1] Bijlsma A Y, Meskers C G, Westendorp R G, et al. Chronology of age-related disease definitions: osteoporosis and sarcopenia[J]. Ageing Res Rev, 2012, 11(2): 320-324.
[2] Compston J E, McClung M R,Leslie W D. Osteoporosis[J]. Lancet, 2019, 393(10169):364-376.
[3] Huang Z, Wei H, Cheng C, et al. Low bone mineral density in chronic hepatitis B virus infection: a case-control study[J]. Pak J Med Sci, 2017, 33(2): 457-461.
[4] Zhou X, Jing X, Zu N, et al. Association between HBV DNA levels and bone mineral density in antiviral-naive chronic hepatitis B patients[J]. Front Endocrinol (Lausanne), 2026, 17: 1714943.
[5] Peng Y, Xi S, and Huang R. Association between hepatitis B virus infection and risk of osteoporosis: a systematic review and meta-analysis[J]. Asian J Surg, 2023, 46(10):4598-4600.
[6] Yang Y, Zeng J, Zhang T, et al. Association between resolved hepatitis B virus infection and femoral and spinal bone mineral density in American adults: a cross-sectional study[J]. Front Endocrinol (Lausanne), 2023, 14:1237618.
[7] Xia S, Qin X, Wang J, et al. Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells[J]. Stem Cell Res Ther, 2023, 14(1):359.
[8] Dessordi R, Watanabe L M, Guimaraes M P, et al. Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use[J]. Sci Rep, 2021, 11(1):10162.
[9] Choudhary N S, Tomar M, Chawla Y K, et al. Hepatic osteodystrophy is common in patients with noncholestatic liver disease[J]. Dig Dis Sci, 2011, 56(11): 3323-3327.
[10] Loosen S H, Killer A, Bock H H, et al. Association between chronic hepatitis B/C and incidence of osteoporosis and bone fractures: results from a retrospective cohort study[J]. J Clin Med, 2024, 13(20).
[11] Zhang Y, Gao X, Liu T, et al. Association between osteoporosis and hepatitis B cirrhosis: a case-control study[J]. Afr Health Sci, 2020, 20(4): 1610-1616.
[12] Kobayashi Y, Uehara S, Udagawa N, et al. Regulation of bone metabolism by Wnt signals[J]. J Biochem, 2016, 159(4):387-392.
[13] Guerra-Menendez L, Sadaba M C, Puche J E, et al. IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand[J]. J Transl Med, 2013, 11:271.
[14] Saeki C, Saito M, Tsubota A. Association of chronic liver disease with bone diseases and muscle weakness[J]. J Bone Miner Metab, 2024, 42(4):399-412.
[15] Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts[J]. Cell, 2007, 130(5):811-823.
[16] Almeida M, Laurent M R, Dubois V, et al. Estrogens and androgens in skeletal physiology and pathophysiology[J]. Physiol Rev, 2017, 97(1): 135-187.
[17] Tu Y, Yang R, Xu X, et al. The microbiota-gut-bone axis and bone health[J]. J Leukoc Biol, 2021, 110(3):525-537.
[18] Ebeling P R, Nguyen H H, Aleksova J, et al. Secondary osteoporosis[J]. Endocr Rev, 2022, 43(2): 240-313.
[19] Yip T C, Lai J C, Yam T F, et al. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B[J]. J Hepatol, 2024, 80(4):553-563. |
